相似文献
1
How will HPV vaccines affect cervical cancer?
Nat Rev Cancer. 2006 Oct;6(10):753-63. doi: 10.1038/nrc1973.
2
[Human papillomavirus prophylactic vaccines: stakes and perspectives].
Gynecol Obstet Fertil. 2006 Jul-Aug;34(7-8):647-55. doi: 10.1016/j.gyobfe.2006.05.008. Epub 2006 Jun 27.
3
Preventive and therapeutic HPV vaccines.
Curr Opin Investig Drugs. 2007 Dec;8(12):1038-50.
4
Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
MMWR Recomm Rep. 2007 Mar 23;56(RR-2):1-24.
5
[Cervical cancer prevention: the impact of HPV vaccination].
Gynecol Obstet Fertil. 2006 Mar;34(3):189-201. doi: 10.1016/j.gyobfe.2006.01.036. Epub 2006 Mar 10.
6
Vaccines against human papillomavirus and cervical cancer: promises and challenges.
Oncologist. 2005 Aug;10(7):528-38. doi: 10.1634/theoncologist.10-7-528.
7
Prevention strategies of cervical cancer in the HPV vaccine era.
Gynecol Oncol. 2006 Oct;103(1):21-4. doi: 10.1016/j.ygyno.2006.07.019. Epub 2006 Aug 17.
8
Papillomavirus-like particle vaccines for cervical cancer.
Mol Med Today. 1999 May;5(5):209-15. doi: 10.1016/S1357-4310(99)01463-X.
9
Human papillomavirus infection: an old disease, a new vaccine.
Aust N Z J Obstet Gynaecol. 2006 Jun;46(3):180-5. doi: 10.1111/j.1479-828X.2006.00580.x.
10
[Vaccination against human papillomavirus for the prevention of cervical cancer].
Ned Tijdschr Geneeskd. 2006 Jun 24;150(25):1380-4.
引用本文的文献
1
Human papilloma virus (HPV) mediated cancers: an insightful update.
J Transl Med. 2025 Apr 29;23(1):483. doi: 10.1186/s12967-025-06470-x.
2
Prophylactic vaccines against HPV-caused cervical cancer: novel vaccines are still demanded.
Infect Agent Cancer. 2025 Mar 10;20(1):16. doi: 10.1186/s13027-025-00643-5.
3
Designing and immunomolecular analysis of a new broad-spectrum multiepitope vaccine against divergent human papillomavirus types.
PLoS One. 2024 Dec 2;19(12):e0311351. doi: 10.1371/journal.pone.0311351. eCollection 2024.
4
An Injection Molded SlipChip with Self-Sampling for Integrated Point-of-Care Testing of Human Papilloma Virus.
Adv Sci (Weinh). 2024 Nov;11(43):e2406367. doi: 10.1002/advs.202406367. Epub 2024 Sep 25.
5
Cancer immunotherapy and its facilitation by nanomedicine.
Biomark Res. 2024 Aug 3;12(1):77. doi: 10.1186/s40364-024-00625-6.
6
Vaccination with a Human Papillomavirus L2 Multimer Provides Broad Protection against 17 Human Papillomavirus Types in the Mouse Cervicovaginal Challenge Model.
Vaccines (Basel). 2024 Jun 20;12(6):689. doi: 10.3390/vaccines12060689.
7
High-Risk Genotypes of Human Papillomavirus at Diverse Anogenital Sites among Chinese Women: Infection Features and Potential Correlation with Cervical Intraepithelial Neoplasia.
Cancers (Basel). 2024 May 31;16(11):2107. doi: 10.3390/cancers16112107.
8
Drug-containing Serum of Quyoufang Promotes Apoptosis of Ectocervical H8 Cells through an E6/p53-related Pathway.
Comb Chem High Throughput Screen. 2025;28(1):122-131. doi: 10.2174/0113862073263350231107105959.
9
Effectiveness of combination therapy with ISA101 vaccine for the treatment of human papillomavirus-induced cervical cancer.
Front Oncol. 2022 Oct 10;12:990877. doi: 10.3389/fonc.2022.990877. eCollection 2022.
10
High Prevalence of HPV 51 in an Unvaccinated Population and Implications for HPV Vaccines.
Vaccines (Basel). 2022 Oct 20;10(10):1754. doi: 10.3390/vaccines10101754.
本文引用的文献
1
IMMUNIZATION OF RABBITS TO INFECTIOUS PAPILLOMATOSIS.
J Exp Med. 1937 Jan 31;65(2):219-31. doi: 10.1084/jem.65.2.219.
2
THE PROGRESSION TO CARCINOMA OF VIRUS-INDUCED RABBIT PAPILLOMAS (SHOPE).
J Exp Med. 1935 Sep 30;62(4):523-48. doi: 10.1084/jem.62.4.523.
3
Condom use and the risk of genital human papillomavirus infection in young women.
N Engl J Med. 2006 Jun 22;354(25):2645-54. doi: 10.1056/NEJMoa053284.
4
Time to clearance of human papillomavirus infection by type and human immunodeficiency virus serostatus.
Int J Cancer. 2006 Oct 1;119(7):1623-9. doi: 10.1002/ijc.22015.
5
Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial.
Lancet. 2006 Apr 15;367(9518):1247-55. doi: 10.1016/S0140-6736(06)68439-0.
6
The promise of the human papillomavirus vaccine does not confer immunity against ethical reflection.
Oncologist. 2006 Apr;11(4):393-6. doi: 10.1634/theoncologist.11-4-393.
7
Ethical analysis of HPV vaccine policy options.
Vaccine. 2006 May 29;24(22):4812-20. doi: 10.1016/j.vaccine.2006.03.019. Epub 2006 Mar 23.
8
Randomized controlled trial of Hepatitis B virus vaccine in HIV-1-infected patients comparing two different doses.
AIDS Res Ther. 2006 Apr 6;3:9. doi: 10.1186/1742-6405-3-9.
9
Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses.
PLoS Med. 2006 May;3(5):e138. doi: 10.1371/journal.pmed.0030138. Epub 2006 Apr 4.
10
The potential of human papillomavirus vaccines.
N Engl J Med. 2006 Mar 16;354(11):1109-12. doi: 10.1056/NEJMp058305.
Zotero 插件